Drugs / SOF/VEL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02994056 | Jan 2017 → Sep 2018 | chronic hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-01-20 | Gilead Sciences | European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) gilead.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOF/VEL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02994056 ↗ |
| Known as | sofosbuvir velpatasvir | “treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks” NCT02994056 ↗ |
| Route | Oral | “400/100 mg FDC tablet administered orally once daily” NCT02994056 ↗ |